CompletedNot Applicable

Moesin Expression in Clear Cell Renal Cell Carcinoma

50 participantsStarted 2017-01-01

Plain-language summary

Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. All cases of ccRCC.
✓. Tissue blocks with material adequate for immunohistochemical evaluation.
✓. All cases with accessible clinical data.

Exclusion criteria

✕. Cases of renal neoplasms other than ccRCC.
✕. Patients who received preoperative chemotherapy or radiotherapy.
✕. Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
✕. Cases with insufficient/destructed material.
✕. Patients with inadequate clinical data.

What they're measuring

Detection of Moesin in renal cell carcinoma

Timeframe: 6 months

Trial details

NCT IDNCT06055660

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-10-31

View on ClinicalTrials.gov More Renal Cell Carcinoma trials